Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the accumulation of tau protein neurofibrillary tangles (NFTs) in the brain. The current treatment options for AD are limited and do not target the underlying cause of the disease. The goal of this project is to develop a novel therapeutic approach for AD by targeting tau protein NFTs using ginger-derived nanovesicles in C. elegans.
Ginger has been shown to have anti-inflammatory and antioxidant properties, which may help reduce tau protein aggregation and neuroinflammation in AD. Nanovesicles are small lipid-based nanoparticles that can be used to deliver drugs or other therapeutic agents to specific tissues in the body. In this study, we will develop ginger-derived nanovesicles loaded with an anti-tau protein antibody and test their efficacy in reducing tau protein aggregation in C. elegans models of AD.
The results of this study could lead to the development of a new therapeutic approach for AD that targets the underlying cause of the disease. This project has the potential to make a significant impact on the field of neurodegenerative diseases and improve the quality of life for patients with AD.
This is a grant proposal that goes into further detail and explains the whole process. The findings from this study could contribute to new breakthroughs in Alzheimer’s therapy, offering a potential alternative to conventional treatments and improving patient outcomes.